Hakim Nasrat A 4
4 · ELITE PHARMACEUTICALS INC /NV/ · Filed Aug 26, 2020
Insider Transaction Report
Form 4
Hakim Nasrat A
DirectorPresident & CEO
Transactions
- Conversion
Series J Convertible Preferred Shares
2020-08-24−24.034→ 0 total→ Common Stock (158,017,321 underlying) - Conversion
Common Stock
2020-08-24+158,017,321→ 167,114,882 total
Holdings
- 2,700,000(indirect: By IRA)
Common Stock
Footnotes (3)
- [F1]The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock, effectively $0.1521 per share of common stock.
- [F2]Shareholder Approval was obtained on June 23, 2020 for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock.
- [F3]None